SOHM, Inc. Appoints Ravi Kapoor as an Independent Director
SOHM Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has announced the appointment of Ravi Kapoor as an Independent Director to its Board. Mr. Kapoor brings over 30 years of experience in corporate law, mergers and acquisitions (M&A), and financial management.
Mr. Kapoor currently serves as the proprietor of Ravi Kapoor & Associates and is a partner at Yan Advisory Services LLP and Amity Consultants LLP. His extensive qualifications include M.Com, LLB, FCS, CAIIB, AMIMA, and PGDIPR. He has previously served on the boards of notable companies including Concord Biotech Limited and Sanghi Industries Limited (an Adani Group enterprise).
SOHM Inc. (OTC PINK:SHMN), un'azienda farmaceutica e biotecnologica, ha annunciato la nomina di Ravi Kapoor come Direttore Indipendente nel suo Consiglio di Amministrazione. Il Sig. Kapoor porta con sé oltre 30 anni di esperienza nel diritto societario, fusioni e acquisizioni (M&A) e gestione finanziaria.
Attualmente, il Sig. Kapoor è titolare di Ravi Kapoor & Associates ed è partner presso Yan Advisory Services LLP e Amity Consultants LLP. Le sue ampie qualifiche comprendono M.Com, LLB, FCS, CAIIB, AMIMA e PGDIPR. In passato ha fatto parte dei consigli di amministrazione di importanti aziende come Concord Biotech Limited e Sanghi Industries Limited (un'impresa del Gruppo Adani).
SOHM Inc. (OTC PINK:SHMN), una empresa farmacéutica y biotecnológica, ha anunciado el nombramiento de Ravi Kapoor como Director Independiente en su Junta Directiva. El Sr. Kapoor aporta más de 30 años de experiencia en derecho corporativo, fusiones y adquisiciones (M&A) y gestión financiera.
Actualmente, el Sr. Kapoor es propietario de Ravi Kapoor & Associates y socio en Yan Advisory Services LLP y Amity Consultants LLP. Sus amplias cualificaciones incluyen M.Com, LLB, FCS, CAIIB, AMIMA y PGDIPR. Anteriormente, ha formado parte de los consejos de administración de empresas destacadas como Concord Biotech Limited y Sanghi Industries Limited (una empresa del Grupo Adani).
SOHM Inc. (OTC PINK:SHMN)는 제약 및 생명공학 회사로, Ravi Kapoor를 독립 이사로 이사회에 선임했다고 발표했습니다. Kapoor 씨는 기업법, 인수합병(M&A), 재무 관리 분야에서 30년 이상의 경험을 보유하고 있습니다.
현재 Kapoor 씨는 Ravi Kapoor & Associates의 소유주이며 Yan Advisory Services LLP와 Amity Consultants LLP의 파트너로 활동 중입니다. 그의 폭넓은 자격에는 M.Com, LLB, FCS, CAIIB, AMIMA, PGDIPR가 포함되어 있습니다. 이전에는 Concord Biotech Limited와 Sanghi Industries Limited(Adani 그룹 소속)의 이사회에서 활동한 바 있습니다.
SOHM Inc. (OTC PINK:SHMN), une entreprise pharmaceutique et biotechnologique, a annoncé la nomination de Ravi Kapoor en tant qu'administrateur indépendant au sein de son conseil d'administration. M. Kapoor apporte plus de 30 ans d'expérience en droit des sociétés, fusions et acquisitions (M&A) et gestion financière.
M. Kapoor est actuellement propriétaire de Ravi Kapoor & Associates et partenaire chez Yan Advisory Services LLP ainsi qu'Amity Consultants LLP. Ses nombreuses qualifications incluent M.Com, LLB, FCS, CAIIB, AMIMA et PGDIPR. Il a précédemment siégé aux conseils d'administration de sociétés renommées telles que Concord Biotech Limited et Sanghi Industries Limited (une entreprise du groupe Adani).
SOHM Inc. (OTC PINK:SHMN), ein Pharma- und Biotechnologieunternehmen, hat die Ernennung von Ravi Kapoor als unabhängigen Direktor in seinen Vorstand bekannt gegeben. Herr Kapoor bringt über 30 Jahre Erfahrung in Gesellschaftsrecht, Fusionen und Übernahmen (M&A) sowie Finanzmanagement mit.
Herr Kapoor ist derzeit Inhaber von Ravi Kapoor & Associates und Partner bei Yan Advisory Services LLP sowie Amity Consultants LLP. Seine umfangreichen Qualifikationen umfassen M.Com, LLB, FCS, CAIIB, AMIMA und PGDIPR. Zuvor war er in den Vorständen namhafter Unternehmen wie Concord Biotech Limited und Sanghi Industries Limited (ein Unternehmen der Adani-Gruppe) tätig.
- Addition of director with over 30 years of experience in corporate law, M&A, and financial management
- Appointment brings expertise in corporate governance as a registered Insolvency Professional
- New director has board experience with prestigious organizations including Adani Group enterprise
- None.
CHINO HILLS, CA / ACCESS Newswire / June 30, 2025 / SOHM, Inc. (OTC PINK:SHMN), a leading pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, health and wellness solutions, proudly announces the appointment of Mr. Ravi Kapoor as an Independent Director. With over three decades of extensive experience in corporate law, mergers and acquisitions (M&A), and financial management, Mr. Kapoor brings a wealth of expertise to the SOHM Board that will enhance the company's strategic vision and governance framework.
Mr. Kapoor is the proprietor of Ravi Kapoor & Associates and a partner at Yan Advisory Services LLP and Amity Consultants LLP. He is a registered Insolvency Professional with the Insolvency & Bankruptcy Board of India, demonstrating his commitment to upholding the highest standards in corporate governance.
He holds multiple qualifications, including M.Com, LLB, FCS, CAIIB, AMIMA, and PGDIPR, which have equipped him with a thorough understanding of the complexities of corporate operations. His professional journey spans various esteemed institutions and includes primary roles as a Company Secretary with notable companies.
Throughout his career, Mr. Kapoor has served on the boards of several prestigious organizations, including Concord Biotech Limited and Sanghi Industries Limited (an Adani Group enterprise), where his contributions have been pivotal in driving growth and innovation.
"I am excited to join the Board of SOHM Inc. and contribute to its ongoing success. I look forward to working with my fellow directors and the management team to explore new opportunities for the company and enhance shareholder value," said Mr. Kapoor.
"We are thrilled to have Mr. Kapoor take this role with SOHM to advance the company's initiatives," stated David Aguilar, COO of SOHM. "His expertise will be vital for the growth and expansion of SOHM."
SOHM Inc. is confident that Mr. Kapoor's experience in navigating complex corporate landscapes will offer invaluable insights as the company continues to advance in its mission to deliver high-quality healthcare and biotechnological solutions.
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted solutions for gene editing. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.
For further information regarding this announcement or to explore potential collaborations, please contact:
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc.
View the original press release on ACCESS Newswire
FAQ
Who is the new Independent Director appointed to SOHM Inc. (SHMN)?
What are Ravi Kapoor's qualifications and current roles?
Which notable companies has SHMN's new director previously served?
What is SOHM Inc. (SHMN)'s main business focus?
